Targeted & controlled bone healing

Sealants provide rapid and reliable closure of tissue membranes to ensure functional integrity after surgery or trauma.

Kuros uses a synthetic matrix technology which combines ease of administration with reliable and pressure resistant, rapid closure of the damaged tissues. Kuros' lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Neuroseal has demonstrated its clinical utility in an EU clinical trial and it received CE Certification in June 2017.

Surgical sealants are used in many surgical procedures where leakage of body fluids or gases have to be minimized. Examples of such uses are the sealing of blood vessels, the gastrointestinal tract, lobes of the lung or of the dura mater surrounding the brain and spinal cord.

Kuros’ technology can be tailored to optimally address the specific needs of a given indication. The most advanced sealant product candidate is designed to address the dural sealant market.

Projections of the medical adhesives and sealant market in the US predict it to reach USD 2.3 billion per annum by 2017 (Global Industry Analysts, Inc, 2012).

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kurosbio.com

About Kuros

  1. Overview
  2. Executive Committee
  3. Board
  4. Careers

Products

  1. MagnetOs

Pipeline

  1. Pipeline
  2. Spinal fusion
    KUR-113
  3. Fracture repair
    KUR-111
    KUR-113
  4. Surgical Sealants
    Neuroseal (KUR-023)

Technologies

  1. Surface Science Technology
  2. Fibrin-Based
  3. Synthetic Cross-Linking Technology
  4. Immune Modulation

Partnerships

  1. Collaborations
  2. Business Development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & Presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Surgical Sealants

Sealants provide rapid and reliable closure of tissue membranes to ensure functional integrity after surgery or trauma.

Kuros uses a synthetic matrix technology which combines ease of administration with reliable and pressure resistant, rapid closure of the damaged tissues. Kuros' lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Neuroseal has demonstrated its clinical utility in an EU clinical trial and it received CE Certification in June 2017.

Surgical sealants are used in many surgical procedures where leakage of body fluids or gases have to be minimized. Examples of such uses are the sealing of blood vessels, the gastrointestinal tract, lobes of the lung or of the dura mater surrounding the brain and spinal cord.

Kuros’ technology can be tailored to optimally address the specific needs of a given indication. The most advanced sealant product candidate is designed to address the dural sealant market.

Projections of the medical adhesives and sealant market in the US predict it to reach USD 2.3 billion per annum by 2017 (Global Industry Analysts, Inc, 2012).